MedPath

Diclofenac

Generic Name
Diclofenac
Brand Names
Aleve Arthritis Pain, Arthrotec, Cambia, Cataflam, Flector, Licart, Lofena, Pennsaid, Previdolrx Analgesic Pak, Salonpas Pain Relieving Patch, Solaraze, Voltaren, Voltaren Emulgel, Xrylix, Zipsor, Zorvolex
Drug Type
Small Molecule
Chemical Formula
C14H11Cl2NO2
CAS Number
15307-86-5
Unique Ingredient Identifier
144O8QL0L1

Overview

Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID). NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of phenylbutazone, mefenamic acid, and indomethacin. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with misoprostol to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).

Indication

Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with misoprostol as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.

Associated Conditions

  • Actinic Keratosis (AK)
  • Acute Arthritis
  • Acute Gouty Arthritis
  • Acute Migraine
  • Acute Musculoskeletal Pain
  • Ankylosing Spondylitis (AS)
  • Common Cold
  • Fever
  • Gout
  • Inflammation
  • Inflammatory Disease of the Oral Cavity
  • Inflammatory Disease of the throat
  • Inflammatory Reaction of the Nerve
  • Joint Pain
  • Juvenile Idiopathic Arthritis (JIA)
  • Menstrual Distress (Dysmenorrhea)
  • Muscle Inflammation
  • Myalgia
  • Neuropathic Pain
  • Ocular Inflammation
  • Osteoarthritis (OA)
  • Osteoarthritis of the Knee
  • Pain
  • Pain caused by Rheumatism
  • Pericarditis
  • Photophobia
  • Postoperative Inflammatory Response
  • Postoperative pain
  • Primary Dysmenorrhoea
  • Radicular Pain
  • Rheumatism
  • Rheumatoid Arthritis
  • Seasonal Allergic Conjunctivitis
  • Spinal pain
  • Tendon pain
  • Vertebral column pain
  • Acute Musculoskeletal injury
  • Acute, moderate, severe Pain, Inflammatory
  • Localized soft tissue rheumatism
  • Mild to moderate joint pain
  • Mild to moderate pain
  • Minor pain
  • Perioperative miosis

Research Report

Published: Jun 4, 2025

Diclofenac: A Comprehensive Pharmacological and Clinical Review

1. Introduction to Diclofenac

1.1. Overview and Summary

Diclofenac is a well-established phenylacetic acid derivative classified as a non-steroidal anti-inflammatory drug (NSAID).[1] It is primarily utilized for the management of signs and symptoms associated with various arthritic conditions, including osteoarthritis and rheumatoid arthritis.[1] Its therapeutic applications extend to ankylosing spondylitis and a range of other painful states, such as menstrual cramps (primary dysmenorrhea) and acute migraine attacks.[2] The pharmacological profile of diclofenac is characterized by its potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities.[3]

The broad spectrum of indications for diclofenac underscores its efficacy in conditions where prostaglandins play a significant pathogenic role. Prostaglandins are key mediators in inflammation, pain sensitization, and fever development. By inhibiting their synthesis, diclofenac offers relief across a diverse array of clinical scenarios. Its utility in both chronic inflammatory diseases like arthritis and acute painful conditions such as migraines highlights its versatility as a therapeutic agent.[1] This versatility is a direct consequence of its fundamental mechanism of action as an NSAID, which targets the cyclooxygenase (COX) enzymes responsible for prostaglandin production. However, this same mechanism also underpins its potential for adverse effects, particularly concerning the gastrointestinal and cardiovascular systems, which are significant enough to warrant boxed warnings from regulatory authorities like the U.S. Food and Drug Administration (FDA).[3] The widespread and long-standing use of diclofenac implies a considerable clinical impact in pain and inflammation management. Concurrently, this extensive use necessitates a comprehensive understanding and careful consideration of its

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Proficient Rx LP
71205-552
TOPICAL
10 mg in 1 g
4/1/2021
Advanced Rx Pharmacy of Tennessee, LLC
80425-0189
ORAL
75 mg in 1 1
2/8/2023
Direct_Rx
72189-454
TOPICAL
16.05 mg in 1 mL
3/29/2023
H. J. Harkins Company Inc.
76519-1159
TOPICAL
10 mg in 1 1
12/8/2017
Amneal Pharmaceuticals LLC
65162-911
TOPICAL
16.05 mg in 1 mL
12/19/2023
Quality Care Products, LLC
55700-980
TOPICAL
30 mg in 1 g
8/18/2022
Quality Care Products, LLC
55700-886
TOPICAL
0.013 g in 1 1
6/26/2023
Bryant Ranch Prepack
71335-1183
ORAL
75 mg in 1 1
2/3/2022
Proficient Rx LP
71205-450
TOPICAL
16.05 mg in 1 mL
4/1/2020
PD-Rx Pharmaceuticals, Inc.
43063-467
ORAL
50 mg in 1 1
3/31/2023

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
VOLTAREN 50 SUPPOSITORY 50 mg
SIN05468P
SUPPOSITORY
50 mg
2/22/1991
Panamax Gel
Hsinchu Plant of UBI Pharma Inc.
SIN13706P
GEL
10.0mg/g
10/8/2009
ALMIRAL GEL 1% w/w
SIN05996P
GEL
1 g/100 g
5/27/1991
FENADIUM TABLETS 25 mg
SIN05568P
ENTERIC COATED TABLET
25 mg
3/7/1991
NEODOL-50 TABLET 50 mg
SIN09392P
ENTERIC COATED TABLET
50 mg
6/19/1997
VOLTAREN 50 TABLET 50 mg
SIN05662P
ENTERIC COATED TABLET
50 mg
4/8/1991
VOREN SUPPOSITORIES 25 mg
SIN07656P
SUPPOSITORY
25 mg
3/8/1994
VOREN CAPSULE 50 mg
SIN07678P
CAPSULE
50 mg
4/5/1994
VOREN TABLET 25 mg
SIN07987P
ENTERIC COATED TABLET
25 mg
1/19/1995
VOREN TABLET 50 mg
SIN07975P
ENTERIC COATED TABLET
50 mg
12/30/1994

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
TEVA-DICLOFENAC SR
teva canada limited
02158582
Tablet (Extended-Release) - Oral
75 MG
12/31/1995
TEVA-DICLOFENAC EC
teva canada limited
00808547
Tablet (Enteric-Coated) - Oral
50 MG
12/31/1989
RIVA-DICLOFENAC 100MG SR TABLETS
laboratoire riva inc.
02240735
Tablet (Extended-Release) - Oral
100 MG
8/27/1999
PMS-DICLOFENAC
02356783
Solution - Topical
1.5 % / W/W
12/2/2014
PMS-DICLOFENAC K
02239753
Tablet - Oral
50 MG
3/4/1999
DICLOFENAC K
sanis health inc
02351684
Tablet - Oral
50 MG
6/15/2010
APO-DICLO SR
02091194
Tablet (Extended-Release) - Oral
100 MG / SRT
12/31/1994
PMS-DICLOFENAC-SR
02231505
Tablet (Extended-Release) - Oral
100 MG
11/28/1997
VOLTAREN EMULGEL JOINT PAIN EXTRA STRENGTH
haleon canada ulc
02465043
Gel - Topical
2.32 % / W/W
6/27/2018
MINT-DICLOFENAC
mint pharmaceuticals inc
02475197
Solution - Ophthalmic
0.1 % / W/V
9/9/2020

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.